Cargando…
Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
Immune-related adverse events (irAEs) following treatment with immune checkpoint inhibitors (ICIs) can affect almost any organ systems. Multiple-organs irAEs are a rare occurrence which makes its management and treatment very challenging. This is a case report of a 71-year-old man with advanced non-...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443792/ https://www.ncbi.nlm.nih.gov/pubmed/34540659 http://dx.doi.org/10.3389/fonc.2021.664809 |
_version_ | 1784568363374084096 |
---|---|
author | Deng, Chao Yang, Meng Jiang, Hong Wang, Renbin Yang, Zhaojun Sun, Hongliang Cui, Huijuan |
author_facet | Deng, Chao Yang, Meng Jiang, Hong Wang, Renbin Yang, Zhaojun Sun, Hongliang Cui, Huijuan |
author_sort | Deng, Chao |
collection | PubMed |
description | Immune-related adverse events (irAEs) following treatment with immune checkpoint inhibitors (ICIs) can affect almost any organ systems. Multiple-organs irAEs are a rare occurrence which makes its management and treatment very challenging. This is a case report of a 71-year-old man with advanced non-small cell lung cancer (NSCLC) who developed multiple-organs irAEs (lung, muscle, myocardium, liver, and pituitary) after a single cycle (21 days) of the BGB-A317 (Tislelizumab). After more than two months of immunosuppression treatment with glucocorticoids, the tumor and inflammatory lesions in the lung were reduced. The levels of serum creatase, cardiac troponin T (TNT), and hepatic transaminase were also reduced. Four months after the termination of ICI therapy, the lung tumor reappeared in the previous site. This rare case report supplies several experiences in the management of multiple-organs irAEs, including full-scale monitoring of immunological indicators, early differential diagnosis, and prompt glucocorticoid therapy. This patient was not a candidate for the ICI re-challenge therapy due to the number and seriousness of irAEs. Multiple-organs irAEs add complexity to the management, and additional research is needed to develop optimal therapeutic guidelines. |
format | Online Article Text |
id | pubmed-8443792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84437922021-09-17 Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report Deng, Chao Yang, Meng Jiang, Hong Wang, Renbin Yang, Zhaojun Sun, Hongliang Cui, Huijuan Front Oncol Oncology Immune-related adverse events (irAEs) following treatment with immune checkpoint inhibitors (ICIs) can affect almost any organ systems. Multiple-organs irAEs are a rare occurrence which makes its management and treatment very challenging. This is a case report of a 71-year-old man with advanced non-small cell lung cancer (NSCLC) who developed multiple-organs irAEs (lung, muscle, myocardium, liver, and pituitary) after a single cycle (21 days) of the BGB-A317 (Tislelizumab). After more than two months of immunosuppression treatment with glucocorticoids, the tumor and inflammatory lesions in the lung were reduced. The levels of serum creatase, cardiac troponin T (TNT), and hepatic transaminase were also reduced. Four months after the termination of ICI therapy, the lung tumor reappeared in the previous site. This rare case report supplies several experiences in the management of multiple-organs irAEs, including full-scale monitoring of immunological indicators, early differential diagnosis, and prompt glucocorticoid therapy. This patient was not a candidate for the ICI re-challenge therapy due to the number and seriousness of irAEs. Multiple-organs irAEs add complexity to the management, and additional research is needed to develop optimal therapeutic guidelines. Frontiers Media S.A. 2021-09-02 /pmc/articles/PMC8443792/ /pubmed/34540659 http://dx.doi.org/10.3389/fonc.2021.664809 Text en Copyright © 2021 Deng, Yang, Jiang, Wang, Yang, Sun and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Deng, Chao Yang, Meng Jiang, Hong Wang, Renbin Yang, Zhaojun Sun, Hongliang Cui, Huijuan Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report |
title | Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report |
title_full | Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report |
title_fullStr | Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report |
title_full_unstemmed | Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report |
title_short | Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report |
title_sort | immune-related multiple-organs injuries following ici treatment with tislelizumab in an advanced non-small cell lung cancer patient: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443792/ https://www.ncbi.nlm.nih.gov/pubmed/34540659 http://dx.doi.org/10.3389/fonc.2021.664809 |
work_keys_str_mv | AT dengchao immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport AT yangmeng immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport AT jianghong immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport AT wangrenbin immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport AT yangzhaojun immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport AT sunhongliang immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport AT cuihuijuan immunerelatedmultipleorgansinjuriesfollowingicitreatmentwithtislelizumabinanadvancednonsmallcelllungcancerpatientacasereport |